Bellerophon Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bellerophon Therapeutics generated cash of -$17,770,000, which is more than the previous year. Cash used in financing activities reached the amount of -$40,000 last year. Net change in cash is therefore -$17,810,000.
Cash Flow
| 2013 | -57.23M | -727K | 57.95M |
|---|---|---|---|
| 2014 | -70.56M | 0 | 87.37M |
| 2015 | -46.26M | -18.30M | 54.01M |
| 2016 | -17.21M | 12.19M | 13.20M |
| 2017 | -15.74M | 2.57M | 27.78M |
| 2018 | -15.49M | 3M | 166K |
| 2019 | -12.93M | 0 | 6.16M |
| 2020 | -19.88M | 0 | 57.56M |
| 2021 | -22.82M | 0 | 0 |
| 2022 | -17.77M | 0 | -40K |
BLPH Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 25.13M | 47.96M | 10.27M | 17.04M | 29.37M | 14.20M | 6.26M | 16.81M | 0 | 0 |
Operating activities | ||||||||||
Net income | -19.83M | -17.75M | -24.72M | -13.26M | 2.81M | -54.81M | -23.81M | -46.45M | -59.67M | -61.99M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 65K | 102K | 147K | 348K | 362K | 373K | 400K | 377K | 388K | 429K |
Stock-based compensation expense | 786K | 1.12M | 1.63M | 2.15M | 2.95M | 2.84M | 2.75M | 1.75M | 1.83M | 1.72M |
| Deferred income tax benefit | 786K | 1.12M | 1.63M | 2.15M | 2.95M | 2.84M | 2.75M | 1.75M | 1.83M | 1.72M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 825K | -5.49M | 2.45M | -406K | 488K | 791K | -1.90M | -1.33M | -2.91M | 0 |
Cash generated by operating activities | -17.77M | -22.82M | -19.88M | -12.93M | -15.49M | -15.74M | -17.21M | -46.26M | -70.56M | -57.23M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -5.98M | 0 | -22.75M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | -22K | -458K | 0 | -727K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 458K | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 3M | 2.57M | 12.19M | -18.30M | 0 | -727K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 54.69M | 6.23M | 0 | 25.25M | 13.33M | 53.82M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -28K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -40K | 0 | 57.56M | 6.16M | 166K | 27.78M | 13.20M | 54.01M | 87.37M | 57.95M |
Net Change In Cash | -17.81M | -22.82M | 37.68M | -6.76M | -12.32M | 14.62M | 8.19M | -10.55M | 16.81M | 0 |
Cash at end of period | 7.32M | 25.13M | 47.96M | 10.27M | 17.04M | 28.82M | 14.45M | 6.26M | 16.81M | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |